US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Warrior Met Coal LLC

46.79

-0.2600-0.55%

Post-market: 46.790.00000.00%18:27 EDT

Volume:798.23K

Turnover:37.19M

Market Cap:2.46B

PE:23.24

High:47.15

Open:46.03

Low:45.77

Close:47.05

Loading ...

Overview Company News Filings

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

Warrior to Provide Updates on Transformational Blue Creek Project via New Dedicated Blue Creek Webpage

THOMSON REUTERS

RBC Cuts Price Target on Warrior Met Coal to $60 From $70, Keeps Sector Perform Rating

MT Newswires Live

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Warrior Met Coal, Inc. (HCC): A Bull Case Theory

Warrior Met Coal price target raised to $67 from $62 at Jefferies

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Warrior Met Coal rises 12.7%

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

BRIEF-Warrior Provides Update On Transformational Blue Creek Steelmaking Coal Project

Warrior Provides Update on Transformational Blue Creek Steelmaking Coal Project

THOMSON REUTERS

Warrior Provides Update on Transformational Blue Creek Steelmaking Coal Project

NAYA Biosciences Announces Nomination of New Board Members

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HCC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HCC\",,,,,undefined,":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":46.79,"timestamp":1749844800000,"preClose":47.05,"halted":0,"volume":798230,"hourTrading":{"tag":"盘后","latestPrice":46.79,"preClose":46.79,"latestTime":"18:27 EDT","volume":16635,"amount":778360.7702,"timestamp":1749853675919},"delay":0,"floatShares":51456964,"shares":52559285,"eps":2.013667,"marketStatus":"Market Closed","change":-0.26,"latestTime":"06-13 16:00:00 EDT","open":46.03,"high":47.1466,"low":45.765,"amount":37188681.593899995,"amplitude":0.029365,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.013667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":47.05,"dividendRate":0.006839,"preHourTrading":{"tag":"盘前","latestPrice":47.28,"preClose":47.055,"latestTime":"09:07 EDT","volume":38,"amount":1778.70989,"timestamp":1749820059557},"postHourTrading":{"tag":"盘后","latestPrice":46.79,"preClose":46.79,"latestTime":"18:27 EDT","volume":16635,"amount":778360.7702,"timestamp":1749853675919},"volumeRatio":1.158188836231644,"impliedVol":0.5868,"impliedVolPercentile":0.86},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HCC\",,,,,undefined,":{"symbol":"HCC","floatShares":51456964,"roa":"2.18%","roe":"5.20%","lyrEps":4.792835,"volumeRatio":1.158188836231644,"shares":52559285,"dividePrice":0.32,"high":47.1466,"amplitude":0.029365,"preClose":47.05,"low":45.765,"week52Low":38,"pbRate":"1.18","psRate":"1.86","week52High":75.53,"institutionHeld":0.9048,"latestPrice":46.79,"eps":2.013667,"divideRate":0.006839,"volume":798230,"delay":0,"ttmEps":2.013667,"open":46.03,"prevYearClose":54.24,"prevWeekClose":47.44,"prevMonthClose":45.45,"prevQuarterClose":47.72,"fiveDayClose":47.44,"twentyDayClose":46.87,"sixtyDayClose":48.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HCC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520182017","title":"Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2520182017","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520182017?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:00","pubTimestamp":1742389200,"startTime":"0","endTime":"0","summary":"FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March  19, 2025  (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045427/0/en/Can-Fite-to-Initiate-Phase-II-Study-in-the-Rare-Genetic-Disease-Lowe-Syndrome-with-Piclidenoson.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2520967508","title":"Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2520967508","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520967508?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:30","pubTimestamp":1742301000,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, March 18, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson.Can-Fite BioPharma Ltd.   is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma , a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-fda-approved-compassionate-treatment-123000979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","BK4006","BK4139","CANF"],"gpt_icon":0},{"id":"2519861436","title":"NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519861436","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519861436?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:30","pubTimestamp":1741897800,"startTime":"0","endTime":"0","summary":"SARASOTA, Fla.andMIAMI, March  13, 2025  (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc.(“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042624/0/en/NAYA-Announces-a-1-12-Reverse-Stock-Split-Effective-Pre-Market-Opening-on-March-18-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ",".IXIC","BK4082","NQmain","BK4006","NAYA","NVIW.SI","QID","MNQmain","SQQQ","USJW.SI","QLD","HCC","USAW.SI","TQQQ","TSYW.SI"],"gpt_icon":1},{"id":"2519859995","title":"Warrior to Provide Updates on Transformational Blue Creek Project via New Dedicated Blue Creek Webpage","url":"https://stock-news.laohu8.com/highlight/detail?id=2519859995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519859995?lang=en_us&edition=fundamental","pubTime":"2025-03-14 00:00","pubTimestamp":1741881600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUAHFM9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4006","HCC"],"gpt_icon":0},{"id":"2519304880","title":"RBC Cuts Price Target on Warrior Met Coal to $60 From $70, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519304880","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519304880?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:13","pubTimestamp":1741864426,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCC"],"gpt_icon":0},{"id":"2518788325","title":"Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518788325?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:12","pubTimestamp":1741637520,"startTime":"0","endTime":"0","summary":"– UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 –。– Post divestiture expected cash of approximately $250 million, with cash runway exceeding two years; Company headcount to be reduced by approximately 30% –。– Catalyst-driven 2025/2026 with multiple clinical data readouts across the Company’s innovative oncology pipeline –。– Conference call today at 5:00 p.m. Eastern Time –。REDWOOD CITY, Calif., March 10, 2025  -- Coherus BioSciences, Inc. , today reported financial results for the fourth quarter and full year 2024 and provided an overview of recent business updates.“Upon the completion of the UDENYCA divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,\"continued Mr. Lanfear. “These efforts, combined with organizational streamlining, are expected to provide Cohe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coherus-biosciences-reports-fourth-quarter-201200398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4189","BK4006","BK4139","CHSCO","HCC","CR","ORR","CHSCL","CHSCM","BK4161","CHSCN","CHRS"],"gpt_icon":0},{"id":"2518277677","title":"EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277677","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277677?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:41","pubTimestamp":1741614060,"startTime":"0","endTime":"0","summary":"Bristol Myers BMY announced that the European Commission  has approved the blockbuster immuno-oncology drug Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma , a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of Lenvima  or Nexavar .HCC accounts for 90% of liver cancer cases worldwide, which is the third most frequent cause of cancer death.In August 2024, the FDA also accepted BMY’s supplemental biologics license application  for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable HCC and assigned a target action date of April 21, 2025.We note that the FDA granted accelerated approval in 2020 for the combination of Opdivo plus Yervoy as a second-line treatment fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ec-approves-bristol-myers-opdivo-134100082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306806265.USD","LU2125154778.USD","BK4568","LU1430594728.SGD","BK4139","LU0320765992.SGD","BMRN","LU1093756168.USD","BK4126","LU1868837136.USD","GILD","LU0321505439.SGD","LU0321505868.SGD","BMY","LU0289739699.SGD","LU0889565916.HKD","BK4566","LU0985481810.HKD","IE00B2B36J28.USD","LU1323610961.USD","LU1670710661.SGD","LU1868836914.USD","LU0225771236.USD","BK4007","LU1670710588.SGD","IE00BZ1G4Q59.USD","LU2360032135.SGD","BK4532","BK4559","LU0109394709.USD","LU1032466523.USD","IE00BSNM7G36.USD","LU2242646821.SGD","IE0009355771.USD","HCC","MYE","LU0306807586.USD","EC","LU0061475181.USD","LU2089984988.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0237698245.USD","LU1261432733.SGD","LU0882574055.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1074936037.SGD","BK4578"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TEN","BK4582","BK4006","BK4500","FLOT","LU1829250122.USD","BK4144","BK4532","LU2236285917.USD","BK4588","LU0320765992.SGD","AZN","CRT","HCC","LU0109394709.USD","BK4585","OS","ALK","BK4124","BK4156","BK4213","BK4008","LU2456880835.USD","BK4097","HSCT","VOD","BTC","BK4132","BK4568","LU0889565916.HKD","BK4007","LU2462157665.USD","LU2417539215.USD"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","LU1670711040.USD","BK4532","LU1571399168.USD","LU2125154935.USD","EC","LU2242646821.SGD","LU1032466523.USD","LU1670710588.SGD","IE00B19Z4B17.USD","BK4132","MYE","OS","LU0321505439.SGD","TEN","HCC","RCC","BK4201","AEIS","LU0306807586.USD","IE00BFTCPJ56.SGD","VOD","ORR","BK4581","LU0225284248.USD","LU0114720955.EUR","LU1868836914.USD","LU0306806265.USD","LU1868837136.USD","LU0096364046.USD","LU1291159041.SGD","IE00B7SZL793.SGD","BMY","LU0237698245.USD","ALK","HSCT","LU0321505868.SGD","BK4213","LU1430594728.SGD","BK4157","LU1868836591.USD","BK4124","BK4097","LU0868494617.USD","CRC","LU1868837300.USD","IE00BSNM7G36.USD","CRT","LU0061475181.USD"],"gpt_icon":0},{"id":"2516968490","title":"Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2516968490","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516968490?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999600,"startTime":"0","endTime":"0","summary":"Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects Ramat Gan, Israel, March  03, 2025  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035375/0/en/Can-Fite-Innovative-Publication-Namodenoson-in-Liver-Cancer-Treatment-Alongside-with-Cardiac-Liver-and-Neurological-Benefits.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2514045184","title":"Warrior Met Coal, Inc. (HCC): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2514045184","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514045184?lang=en_us&edition=fundamental","pubTime":"2025-02-26 03:43","pubTimestamp":1740512594,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Warrior Met Coal, Inc.  on Substack by Unemployed Value Degen. In this article, we will summarize the bulls’ thesis on HCC. Warrior Met Coal, Inc. 's share was trading at $49.80 as of Feb 24th. HCC’s trailing and forward P/E were 10.40 and 5.13 respectively according to Yahoo Finance.Warrior Met Coal  recently sold off following its earnings report, despite its strong fundamentals and shareholder-aligned management. This reaction highlights the short-term nature of commodity markets, which are not forward-looking in the way equity markets typically are. While coking coal prices are currently depressed, macroeconomic tailwinds are forming—China is stimulating, India is growing at 7% annually, and Trump is back in office. These factors could support a significant rebound in coal demand over the next few years. Although prices are not at the generational lows seen in 2021, Warrior Met Coal remains a compelling investment, with the potential to double in va","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/warrior-met-coal-inc-hcc-194314246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","HCC"],"gpt_icon":0},{"id":"2514010953","title":"Warrior Met Coal price target raised to $67 from $62 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2514010953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514010953?lang=en_us&edition=fundamental","pubTime":"2025-02-26 02:21","pubTimestamp":1740507679,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Warrior Met Coal (HCC) to $67 from $62 and keeps a Buy rating on the shares after the company issued a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-price-target-raised-to-67-from-62-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-price-target-raised-to-67-from-62-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2514099842","title":"NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099842","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099842?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell Technology. For many individuals and couples struggling with infertility, the high cost of IVF often makes treatment financially out of reach. The lack of comprehensive insurance coverage for fertility services in most states further compounds this challenge, forcing many patients to take on significant debt or forego treatment altogether.About NAYA Women’s HealthNAYA Women’s Health is currently focused within the fertility marketplace. Our commercial strategy includes operating fertility-focused clinics providing treatment to patients via INVO Centers, LLC, our wholly owned subsidiary. We currently have two operational INVO Centers in the United States along with a conventional IVF clinic.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/naya-biosciences-supports-recent-executive-130000569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","NAYA","BK4006","BK4082"],"gpt_icon":0},{"id":"2514509829","title":"FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514509829","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514509829?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:45","pubTimestamp":1740483900,"startTime":"0","endTime":"0","summary":"Acceptance based on results from the KEYNOTE-689 trial: the first Phase 3 trial to demonstrate significant improvement in event-free survival in the neoadjuvant and adjuvant setting for an anti-PD-1 therapy in earlier stages of head and neck squamous cell carcinoma. RAHWAY, N.J., February 25, 2025----Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration  has accepted for priority review a new supplemental Biologics License Application  seeking approval for KEYTRUDA , Merck’s anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma  as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act , or target action, date of June 23, 2025.KEYTRUDA is currently approved as monotherapy and in combination regimens for a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-priority-review-merck-114500312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU0320765646.SGD","BK4534","LU1989771016.USD","LU0006306889.USD","LU2361045086.USD","LU0238689110.USD","SMP","BK4139","BK4533","LU0265550359.USD","LU0965509101.SGD","LU1037948541.HKD","LU0861579265.USD","CPS","LU1291159041.SGD","IE00BBT3K403.USD","LU1878469433.USD","RCC","LU0265550946.USD","LU2106854487.HKD","BK4585","LU1989772923.USD","HCC","CRC","CRT","LU0456854461.SGD","LU1093756325.SGD","BCG","LU2089984988.USD","SG9999015358.SGD","ALT","IE00B1BXHZ80.USD","HSCT","DM","LU2023250504.SGD","LU1066053197.SGD","LU0122379950.USD","LU1066051225.USD","LU1066051498.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","MRK","AEIS","IE00BLSP4239.USD","LU1116320737.USD","BTC","SG9999002224.SGD","SG9999013999.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2513572013","title":"Warrior Met Coal rises 12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513572013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513572013?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:50","pubTimestamp":1740408647,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) is up 12.7%, or $5.87 to $52.00. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-rises-12-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-rises-12-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4006","HCC"],"gpt_icon":0},{"id":"2513051728","title":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513051728","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513051728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:59","pubTimestamp":1740398340,"startTime":"0","endTime":"0","summary":"Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and investigator’s choice of chemotherapy. The U.S. Food and Drug Administration assigned a target action date of June 23, 2025. U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. Opdivo plus Yervoy received approval from the U.S. FDA in July 2018 for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Opdivo plus Yervoy was also approved in December 2024 in the European Union for the first-line treatment of adult patients with MSI-H or dMMR unresectable or mCRC and in October","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","IE00B2B36J28.USD","BK4008","LU1868836591.USD","LU1868836757.USD","BK4581","LU1291159041.SGD","LU1323610961.USD","LU2242652126.USD","LU1093756168.USD","BK4534","LU0061475181.USD","BK4532","CRT","BK4195","LU2133065610.SGD","BK4559","BK4211","IE0009355771.USD","LU1670710588.SGD","BMY","PFS","BK4144","LU0096364046.USD","LU0985481810.HKD","LU1261432733.SGD","LU0266512127.USD","CRC","ALK","LU1670711123.USD","LU1032466523.USD","BK4126","LU1074936037.SGD","LU0868494617.USD","LU1585245621.USD","LU2360032135.SGD","VOD","IE00BFTCPJ56.SGD","HCC","LU1868837136.USD","LU2125154778.USD","HSCT","BK4585","IE00BJT1NW94.SGD","LU2242646821.SGD","RCC","BK4124","TEN","MYE","LU0882574055.USD"],"gpt_icon":0},{"id":"2513454472","title":"BRIEF-Warrior Provides Update On Transformational Blue Creek Steelmaking Coal Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2513454472","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513454472?lang=en_us&edition=fundamental","pubTime":"2025-02-22 06:59","pubTimestamp":1740178782,"startTime":"0","endTime":"0","summary":"BRIEF-Warrior Provides Update On Transformational Blue Creek Steelmaking Coal ProjectFeb 21 (Reuters) - Warrior Met Coal Inc HCC.N:WARRIOR PROVIDES UPDATE ON TRANSFORMATIONAL BLUE CREEK STEELMAKING COAL PROJECTSource text: ID:nBwbNFSnJaFurther company coverage: HCC.N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nTUA7HX5QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2513321098","title":"Warrior Provides Update on Transformational Blue Creek Steelmaking Coal Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2513321098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513321098?lang=en_us&edition=fundamental","pubTime":"2025-02-22 05:30","pubTimestamp":1740173400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nTUA7HX5QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2513107662","title":"Warrior Provides Update on Transformational Blue Creek Steelmaking Coal Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2513107662","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513107662?lang=en_us&edition=fundamental","pubTime":"2025-02-22 05:30","pubTimestamp":1740173400,"startTime":"0","endTime":"0","summary":"Implementation of Innovative Technologies and Best Practices Significantly Increases Nameplate Capacity. BROOKWOOD, Ala., February 21, 2025----Warrior Met Coal, Inc.   today provided several positive operational and financial updates regarding its progress towards developing its world-class Blue Creek project. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry.Nameplate capacity increased 25% to 6.0 million short tons per year from original production plan of 4.8 million short tons per year;At revised nameplate capacity, Blue Creek is expected to generate approximately $1.3 billion of incremental revenues, $735 million of incremental adjusted EBITDA, and $637 million of incremental free cash flows annually;On track for shorter production timeline, with the first longwall expected to start no later than Q2 2026; and. Warrior has the ability to increase the current nameplate capacity 83%, an additional 0.6 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/warrior-provides-transformational-blue-creek-213000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","HCC"],"gpt_icon":0},{"id":"2512110020","title":"NAYA Biosciences Announces Nomination of New Board Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2512110020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512110020?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:15","pubTimestamp":1739974500,"startTime":"0","endTime":"0","summary":"New board reflects company’s added focus on oncology & autoimmune diseases. SARASOTA, Fla. and MIAMI, Feb. 19, 2025  -- NAYA Biosciences  , a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025.Daniel Teper, PharmD, MBA is the Founder & President of NAYA Biosciences. He is also the Executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/naya-biosciences-announces-nomination-board-141500586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QQQ","USAW.SI","MNQmain","BK4082","BK4006","BDTX","TSYW.SI","TQQQ","SQQQ","HCC","BK4139","NVIW.SI",".IXIC","USJW.SI","QID","KYMR","NQmain","QLD","NAYA","PSQ"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":138,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HCC\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"HCC","amount":0.08,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-05","defaultRemindTime":1746451800000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-05-05","currency":"USD","dateTimestamp":1746417600000,"payDate":"2025-05-12"},{"market":"US","date":"2025-04-30","symbol":"HCC","fiscalQuarterEnding":"2025/03","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745985600000,"reportTimeType":"post","actualEps":-0.16},{"date":"2025-02-24","symbol":"HCC","amount":0.08,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"},{"date":"2025-02-13","symbol":"HCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.53,"defaultRemindTime":1739480400000,"name":null,"time":"Post Market","dateTimestamp":1739422800000,"actualEps":null},{"date":"2024-11-05","symbol":"HCC","amount":0.08,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-05","defaultRemindTime":1730817000000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-12","payableDate":"2024-11-05","currency":"USD","dateTimestamp":1730782800000,"payDate":"2024-11-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HCC\",market:\"US\",,,undefined,":[{"executeDate":"2017-05-25","recordDate":"2017-05-30","paymentDate":"2017-06-13","value":0.05,"currency":"USD"},{"executeDate":"2017-08-10","recordDate":"2017-08-14","paymentDate":"2017-08-23","value":0.05,"currency":"USD"},{"executeDate":"2017-11-02","recordDate":"2017-11-03","paymentDate":"2017-11-10","value":0.05,"currency":"USD"},{"executeDate":"2017-11-24","recordDate":"2017-11-13","paymentDate":"2017-11-22","value":11.21,"currency":"USD"},{"executeDate":"2018-02-22","recordDate":"2018-02-23","paymentDate":"2018-03-02","value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.1667,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1667,"analysts":6,"updateTime":1712808000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HCC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HCC","date":"2025-06-13","current":23.45195,"percent":0.921697,"low":-75.380251,"twenty":-10.643728,"median":5.376398,"eighty":9.974476,"high":69.41615,"avg":2.443255,"sd":22.92253,"marketCap":2472914359},"quantilePoints":[{"date":"2020-06-19","current":3.626033,"twenty":1.655772,"median":2.53894,"eighty":3.173533,"marketCap":771608870},{"date":"2020-06-26","current":3.556301,"twenty":1.658309,"median":2.569547,"eighty":3.223807,"marketCap":756770238},{"date":"2020-07-02","current":3.58756,"twenty":1.668892,"median":2.578348,"eighty":3.233908,"marketCap":763422039},{"date":"2020-07-10","current":3.674123,"twenty":1.672645,"median":2.581956,"eighty":3.266791,"marketCap":781842410},{"date":"2020-07-17","current":3.823204,"twenty":1.67604,"median":2.584621,"eighty":3.281873,"marketCap":813566382},{"date":"2020-07-24","current":3.830418,"twenty":1.677444,"median":2.593675,"eighty":3.321451,"marketCap":815101413},{"date":"2020-07-31","current":3.828013,"twenty":1.678223,"median":2.601117,"eighty":3.349079,"marketCap":814589736},{"date":"2020-08-07","current":9.647015,"twenty":1.680377,"median":2.606673,"eighty":3.362554,"marketCap":753962429},{"date":"2020-08-14","current":10.295388,"twenty":1.681997,"median":2.613044,"eighty":3.385333,"marketCap":804636075},{"date":"2020-08-21","current":9.561875,"twenty":1.685395,"median":2.623886,"eighty":3.399229,"marketCap":747308314},{"date":"2020-08-28","current":10.177502,"twenty":1.686175,"median":2.628223,"eighty":3.407979,"marketCap":795422685},{"date":"2020-09-04","current":11.087845,"twenty":1.686798,"median":2.636324,"eighty":3.421132,"marketCap":866570531},{"date":"2020-09-11","current":11.716571,"twenty":1.68751,"median":2.638037,"eighty":3.438505,"marketCap":915708612},{"date":"2020-09-18","current":13.622397,"twenty":1.688347,"median":2.640623,"eighty":3.481761,"marketCap":1064658420},{"date":"2020-09-25","current":11.592136,"twenty":1.6895,"median":2.654273,"eighty":3.510467,"marketCap":905983367},{"date":"2020-10-02","current":11.461151,"twenty":1.692021,"median":2.657169,"eighty":3.536003,"marketCap":895746267},{"date":"2020-10-09","current":10.852073,"twenty":1.693794,"median":2.659661,"eighty":3.541374,"marketCap":848143751},{"date":"2020-10-16","current":9.981025,"twenty":1.69644,"median":2.662192,"eighty":3.558021,"marketCap":780067035},{"date":"2020-10-23","current":9.77145,"twenty":1.699397,"median":2.668416,"eighty":3.571019,"marketCap":763687674},{"date":"2020-10-30","current":41.058448,"twenty":1.701282,"median":2.677261,"eighty":3.586328,"marketCap":767792985},{"date":"2020-11-06","current":46.094951,"twenty":1.702293,"median":2.681102,"eighty":3.595833,"marketCap":861975591},{"date":"2020-11-13","current":47.518311,"twenty":1.702545,"median":2.691141,"eighty":3.610915,"marketCap":888592414},{"date":"2020-11-20","current":45.301155,"twenty":1.705418,"median":2.698396,"eighty":3.630957,"marketCap":847131593},{"date":"2020-11-27","current":50.501891,"twenty":1.708225,"median":2.702029,"eighty":3.645226,"marketCap":944385371},{"date":"2020-12-04","current":50.200796,"twenty":1.712405,"median":2.708224,"eighty":3.651736,"marketCap":938754889},{"date":"2020-12-11","current":53.266494,"twenty":1.718193,"median":2.715221,"eighty":3.674123,"marketCap":996083432},{"date":"2020-12-18","current":52.116857,"twenty":1.724567,"median":2.722503,"eighty":3.681994,"marketCap":974585228},{"date":"2020-12-24","current":54.41613,"twenty":1.731322,"median":2.730143,"eighty":3.690191,"marketCap":1017581636},{"date":"2020-12-31","current":58.357741,"twenty":1.733792,"median":2.736533,"eighty":3.700573,"marketCap":1091289762},{"date":"2021-01-08","current":62.573075,"twenty":1.734571,"median":2.739414,"eighty":3.729427,"marketCap":1170116509},{"date":"2021-01-15","current":63.011032,"twenty":1.734571,"median":2.74358,"eighty":3.73653,"marketCap":1178306300},{"date":"2021-01-22","current":63.750084,"twenty":1.737638,"median":2.753445,"eighty":3.748375,"marketCap":1192126574},{"date":"2021-01-29","current":63.011032,"twenty":1.738451,"median":2.763997,"eighty":3.76196,"marketCap":1178306300},{"date":"2021-02-05","current":59.917962,"twenty":1.739084,"median":2.770528,"eighty":3.795059,"marketCap":1120465896},{"date":"2021-02-12","current":59.972707,"twenty":1.751068,"median":2.780387,"eighty":3.813586,"marketCap":1121489620},{"date":"2021-02-19","current":62.217235,"twenty":1.754476,"median":2.788807,"eighty":3.819331,"marketCap":1163462303},{"date":"2021-02-26","current":-27.522655,"twenty":1.738929,"median":2.788676,"eighty":3.821762,"marketCap":984237661},{"date":"2021-03-05","current":-29.015798,"twenty":1.734259,"median":2.773691,"eighty":3.819331,"marketCap":1037633966},{"date":"2021-03-12","current":-27.623155,"twenty":1.713828,"median":2.767514,"eighty":3.815896,"marketCap":987831643},{"date":"2021-03-19","current":-26.824757,"twenty":1.702293,"median":2.759626,"eighty":3.813856,"marketCap":959280129},{"date":"2021-03-26","current":-24.598934,"twenty":1.693794,"median":2.745406,"eighty":3.813586,"marketCap":879682474},{"date":"2021-04-01","current":-24.21121,"twenty":1.688191,"median":2.743396,"eighty":3.812219,"marketCap":865817076},{"date":"2021-04-09","current":-24.21121,"twenty":1.683836,"median":2.738063,"eighty":3.806727,"marketCap":865817076},{"date":"2021-04-16","current":-26.724236,"twenty":1.677132,"median":2.73151,"eighty":3.800096,"marketCap":955685396},{"date":"2021-04-23","current":-25.101539,"twenty":1.656787,"median":2.726002,"eighty":3.796478,"marketCap":897656138},{"date":"2021-04-30","current":-22.760835,"twenty":1.647197,"median":2.715477,"eighty":3.791464,"marketCap":813950217},{"date":"2021-05-07","current":-10.548309,"twenty":1.639558,"median":2.709968,"eighty":3.783289,"marketCap":829740549},{"date":"2021-05-14","current":-10.633271,"twenty":1.625315,"median":2.703037,"eighty":3.772709,"marketCap":836423714},{"date":"2021-05-21","current":-11.417532,"twenty":1.623446,"median":2.698396,"eighty":3.763727,"marketCap":898114461},{"date":"2021-05-28","current":-11.959979,"twenty":1.618983,"median":2.691141,"eighty":3.76092,"marketCap":940783894},{"date":"2021-06-04","current":-12.639672,"twenty":1.616389,"median":2.684106,"eighty":3.7594,"marketCap":994249209},{"date":"2021-06-11","current":-11.646274,"twenty":1.610217,"median":2.677633,"eighty":3.754101,"marketCap":916107595},{"date":"2021-06-18","current":-10.679019,"twenty":1.607185,"median":2.669809,"eighty":3.752198,"marketCap":840022341},{"date":"2021-06-25","current":-11.59399,"twenty":1.60173,"median":2.662192,"eighty":3.7471,"marketCap":911994879},{"date":"2021-07-02","current":-11.299893,"twenty":1.598085,"median":2.660741,"eighty":3.746622,"marketCap":888860849},{"date":"2021-07-09","current":-11.541706,"twenty":1.592628,"median":2.658582,"eighty":3.744712,"marketCap":907882162},{"date":"2021-07-16","current":-11.20186,"twenty":1.586716,"median":2.65578,"eighty":3.73653,"marketCap":881149505},{"date":"2021-07-23","current":-11.567848,"twenty":1.582047,"median":2.642877,"eighty":3.73653,"marketCap":909938521},{"date":"2021-07-30","current":-12.201793,"twenty":1.573919,"median":2.638293,"eighty":3.733802,"marketCap":959805208},{"date":"2021-08-06","current":-13.112285,"twenty":1.568818,"median":2.637581,"eighty":3.733802,"marketCap":972682403},{"date":"2021-08-13","current":-12.446968,"twenty":1.562592,"median":2.631646,"eighty":3.729427,"marketCap":923328539},{"date":"2021-08-20","current":-13.015259,"twenty":1.533021,"median":2.623886,"eighty":3.72251,"marketCap":965484964},{"date":"2021-08-27","current":-15.461685,"twenty":1.519792,"median":2.616296,"eighty":3.703801,"marketCap":1146963235},{"date":"2021-09-03","current":-17.090325,"twenty":1.517791,"median":2.607623,"eighty":3.702437,"marketCap":1267777381},{"date":"2021-09-10","current":-18.330863,"twenty":1.506877,"median":2.604719,"eighty":3.700946,"marketCap":1359801773},{"date":"2021-09-17","current":-16.182445,"twenty":1.50136,"median":2.597695,"eighty":3.699883,"marketCap":1200429921},{"date":"2021-09-24","current":-14.990419,"twenty":1.491466,"median":2.590275,"eighty":3.69463,"marketCap":1112004248},{"date":"2021-10-01","current":-17.665547,"twenty":1.437809,"median":2.583354,"eighty":3.691387,"marketCap":1310447909},{"date":"2021-10-08","current":-18.62887,"twenty":1.417229,"median":2.579596,"eighty":3.688084,"marketCap":1381908192},{"date":"2021-10-15","current":-18.317003,"twenty":-4.135408,"median":2.572321,"eighty":3.686335,"marketCap":1358773568},{"date":"2021-10-22","current":-17.603173,"twenty":-4.510213,"median":2.5394,"eighty":3.684309,"marketCap":1305820985},{"date":"2021-10-29","current":-16.612128,"twenty":-4.706327,"median":2.532428,"eighty":3.680121,"marketCap":1232304291},{"date":"2021-11-05","current":-54.762812,"twenty":-4.859084,"median":2.521967,"eighty":3.677059,"marketCap":1167543151},{"date":"2021-11-12","current":-54.979838,"twenty":-4.941339,"median":2.515293,"eighty":3.676527,"marketCap":1172170138},{"date":"2021-11-19","current":-50.808122,"twenty":-5.127728,"median":2.433754,"eighty":3.674604,"marketCap":1083229158},{"date":"2021-11-26","current":-51.362743,"twenty":-5.252528,"median":2.414858,"eighty":3.674123,"marketCap":1095053682},{"date":"2021-12-03","current":-53.123062,"twenty":-5.611529,"median":2.40502,"eighty":3.665747,"marketCap":1132583691},{"date":"2021-12-10","current":-54.232305,"twenty":-5.755373,"median":2.350665,"eighty":3.656822,"marketCap":1156232737},{"date":"2021-12-17","current":-57.415348,"twenty":-10.37185,"median":2.326995,"eighty":3.653327,"marketCap":1224095219},{"date":"2021-12-23","current":-61.56295,"twenty":-10.599286,"median":2.309178,"eighty":3.651736,"marketCap":1312522089},{"date":"2021-12-31","current":-61.997001,"twenty":-10.714311,"median":2.30567,"eighty":3.650401,"marketCap":1321776064},{"date":"2022-01-07","current":-62.551622,"twenty":-10.856785,"median":2.304,"eighty":3.648657,"marketCap":1333600587},{"date":"2022-01-14","current":-66.55454,"twenty":-11.03063,"median":2.299612,"eighty":3.646023,"marketCap":1418942799},{"date":"2022-01-21","current":-62.334597,"twenty":-11.190096,"median":2.295173,"eighty":3.645248,"marketCap":1328973600},{"date":"2022-01-28","current":-63.443839,"twenty":-11.25153,"median":2.293323,"eighty":3.644889,"marketCap":1352622647},{"date":"2022-02-04","current":-69.327646,"twenty":-11.379626,"median":2.286804,"eighty":3.642707,"marketCap":1478065416},{"date":"2022-02-11","current":-73.981641,"twenty":-11.424067,"median":2.276675,"eighty":3.635881,"marketCap":1577288590},{"date":"2022-02-18","current":-75.380251,"twenty":-11.527328,"median":2.273681,"eighty":3.62589,"marketCap":1607106953},{"date":"2022-02-25","current":10.752414,"twenty":-11.5221,"median":2.276675,"eighty":3.645162,"marketCap":1622334987},{"date":"2022-03-04","current":13.090637,"twenty":-11.476351,"median":2.285809,"eighty":3.650617,"marketCap":1975128468},{"date":"2022-03-11","current":14.234148,"twenty":-11.443674,"median":2.292953,"eighty":3.674123,"marketCap":2147662506},{"date":"2022-03-18","current":13.142137,"twenty":-11.424067,"median":2.295173,"eighty":3.679184,"marketCap":1982898730},{"date":"2022-03-25","current":13.066882,"twenty":-11.424067,"median":2.299612,"eighty":3.690894,"marketCap":1971544287},{"date":"2022-04-01","current":12.971104,"twenty":-11.417532,"median":2.304,"eighty":3.702437,"marketCap":1957093177},{"date":"2022-04-08","current":12.868485,"twenty":-11.39139,"median":2.30567,"eighty":3.733802,"marketCap":1941609845},{"date":"2022-04-14","current":13.569718,"twenty":-11.386161,"median":2.308491,"eighty":3.738166,"marketCap":2047412614},{"date":"2022-04-22","current":11.298406,"twenty":-11.36394,"median":2.326995,"eighty":3.75363,"marketCap":1704714864},{"date":"2022-04-29","current":11.654154,"twenty":-11.348255,"median":2.350665,"eighty":3.7679,"marketCap":1758390415},{"date":"2022-05-06","current":5.191508,"twenty":-11.309043,"median":2.40502,"eighty":3.798629,"marketCap":1653417395},{"date":"2022-05-13","current":5.197995,"twenty":-11.263294,"median":2.414858,"eighty":3.813721,"marketCap":1655483521},{"date":"2022-05-20","current":5.376398,"twenty":-11.243687,"median":2.472508,"eighty":3.823204,"marketCap":1712301988},{"date":"2022-05-27","current":5.592102,"twenty":-11.241073,"median":2.517292,"eighty":3.828494,"marketCap":1781000680},{"date":"2022-06-03","current":5.866193,"twenty":-11.217545,"median":2.521967,"eighty":3.839442,"marketCap":1868294507},{"date":"2022-06-10","current":5.890521,"twenty":-11.197938,"median":2.532428,"eighty":3.86219,"marketCap":1876042480},{"date":"2022-06-17","current":5.476952,"twenty":-11.179639,"median":2.5394,"eighty":3.887139,"marketCap":1744326943},{"date":"2022-06-24","current":5.214214,"twenty":-11.122126,"median":2.569547,"eighty":3.909261,"marketCap":1660648836},{"date":"2022-07-01","current":4.816863,"twenty":-11.046315,"median":2.578972,"eighty":4.004025,"marketCap":1534098614},{"date":"2022-07-08","current":4.666032,"twenty":-11.034551,"median":2.581956,"eighty":4.305553,"marketCap":1486061183},{"date":"2022-07-15","current":4.907686,"twenty":-11.001874,"median":2.584621,"eighty":4.638461,"marketCap":1563024379},{"date":"2022-07-22","current":4.828216,"twenty":-10.933904,"median":2.593675,"eighty":4.813944,"marketCap":1537714335},{"date":"2022-07-29","current":5.178533,"twenty":-10.929983,"median":2.601117,"eighty":4.897306,"marketCap":1649285143},{"date":"2022-08-05","current":2.424599,"twenty":-10.885542,"median":2.602918,"eighty":4.942718,"marketCap":1503634374},{"date":"2022-08-12","current":2.78275,"twenty":-10.769209,"median":2.601117,"eighty":4.897306,"marketCap":1725744570},{"date":"2022-08-19","current":2.883532,"twenty":-10.762674,"median":2.606673,"eighty":4.850273,"marketCap":1788245347},{"date":"2022-08-26","current":2.90602,"twenty":-10.753524,"median":2.613044,"eighty":4.828216,"marketCap":1802191801},{"date":"2022-09-02","current":2.655315,"twenty":-10.726075,"median":2.623886,"eighty":4.825945,"marketCap":1646714663},{"date":"2022-09-09","current":2.606173,"twenty":-10.679019,"median":2.621717,"eighty":4.816863,"marketCap":1616239078},{"date":"2022-09-16","current":2.333812,"twenty":-10.659413,"median":2.607733,"eighty":4.802266,"marketCap":1447332022},{"date":"2022-09-23","current":2.248855,"twenty":-10.646342,"median":2.605949,"eighty":4.683872,"marketCap":1394645418},{"date":"2022-09-30","current":2.368795,"twenty":-10.633271,"median":2.601176,"eighty":4.666032,"marketCap":1469027473},{"date":"2022-10-07","current":2.692797,"twenty":-10.548309,"median":2.602947,"eighty":4.640083,"marketCap":1669959853},{"date":"2022-10-14","current":2.765261,"twenty":-10.509096,"median":2.606173,"eighty":4.631973,"marketCap":1714898457},{"date":"2022-10-21","current":3.075936,"twenty":-10.450277,"median":2.610389,"eighty":4.409781,"marketCap":1907566266},{"date":"2022-10-28","current":3.08843,"twenty":-10.319566,"median":2.623886,"eighty":4.385454,"marketCap":1915314301},{"date":"2022-11-04","current":2.888992,"twenty":-6.057648,"median":2.626492,"eighty":4.335369,"marketCap":1964901726},{"date":"2022-11-11","current":2.590524,"twenty":-5.933659,"median":2.635068,"eighty":4.24592,"marketCap":1761903204},{"date":"2022-11-18","current":2.532805,"twenty":-5.933659,"median":2.635068,"eighty":4.24592,"marketCap":1722646492},{"date":"2022-11-25","current":2.695329,"twenty":-5.2582,"median":2.638393,"eighty":4.24592,"marketCap":1833185128},{"date":"2022-12-02","current":2.967976,"twenty":-5.2582,"median":2.645964,"eighty":4.24592,"marketCap":2018621437},{"date":"2022-12-09","current":2.695329,"twenty":-5.2582,"median":2.656981,"eighty":4.24592,"marketCap":1833185128},{"date":"2022-12-16","current":2.63761,"twenty":-5.2582,"median":2.657169,"eighty":4.24592,"marketCap":1793928416},{"date":"2022-12-23","current":2.75153,"twenty":-5.18405,"median":2.661998,"eighty":4.24592,"marketCap":1871408768},{"date":"2022-12-30","current":2.630775,"twenty":1.404132,"median":2.662192,"eighty":4.24592,"marketCap":1789279595},{"date":"2023-01-06","current":2.629256,"twenty":1.404132,"median":2.658582,"eighty":4.24592,"marketCap":1788246524},{"date":"2023-01-13","current":2.614826,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1778432346},{"date":"2023-01-20","current":2.909498,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1978848190},{"date":"2023-01-27","current":2.806211,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1908599337},{"date":"2023-02-03","current":2.875322,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1955604084},{"date":"2023-02-10","current":2.913295,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1981430868},{"date":"2023-02-17","current":3.373053,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2163132093},{"date":"2023-02-24","current":2.987654,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1915976338},{"date":"2023-03-03","current":3.436207,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2203632406},{"date":"2023-03-10","current":3.066191,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1966342111},{"date":"2023-03-17","current":2.689033,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1724471348},{"date":"2023-03-24","current":2.800096,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1795696122},{"date":"2023-03-31","current":2.976014,"twenty":1.406003,"median":2.65495,"eighty":4.216104,"marketCap":1908512005},{"date":"2023-04-06","current":2.906296,"twenty":1.406003,"median":2.65495,"eighty":4.216104,"marketCap":1863801563},{"date":"2023-04-14","current":3.133287,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2009370443},{"date":"2023-04-21","current":3.063568,"twenty":1.404132,"median":2.656974,"eighty":4.24592,"marketCap":1964660001},{"date":"2023-04-28","current":2.771722,"twenty":1.404132,"median":2.657169,"eighty":4.24592,"marketCap":1777500012},{"date":"2023-05-05","current":2.740192,"twenty":1.404132,"median":2.658582,"eighty":4.24592,"marketCap":1856003230},{"date":"2023-05-19","current":2.709489,"twenty":-3.288715,"median":2.658582,"eighty":4.355403,"marketCap":1835207675},{"date":"2023-05-26","current":2.572864,"twenty":-3.288715,"median":2.658582,"eighty":4.355403,"marketCap":1742667458},{"date":"2023-06-02","current":2.563653,"twenty":-3.288715,"median":2.656144,"eighty":4.355403,"marketCap":1736428792},{"date":"2023-06-09","current":2.740192,"twenty":-3.288715,"median":2.656144,"eighty":4.355403,"marketCap":1856003230},{"date":"2023-06-16","current":2.770894,"twenty":-3.288715,"median":2.656977,"eighty":4.355403,"marketCap":1876798784},{"date":"2023-06-23","current":2.906753,"twenty":-5.632332,"median":2.661998,"eighty":4.36542,"marketCap":1968819112},{"date":"2023-06-30","current":2.978903,"twenty":-7.975949,"median":2.667532,"eighty":4.375437,"marketCap":2017688665},{"date":"2023-07-07","current":2.974298,"twenty":-7.975949,"median":2.669576,"eighty":4.375437,"marketCap":2014569332},{"date":"2023-07-14","current":3.000395,"twenty":-7.975949,"median":2.674943,"eighty":4.375437,"marketCap":2032245553},{"date":"2023-07-21","current":3.103248,"twenty":-7.975949,"median":2.685979,"eighty":4.375437,"marketCap":2101910660},{"date":"2023-07-28","current":3.259063,"twenty":-7.975949,"median":2.685979,"eighty":4.375437,"marketCap":2207448099},{"date":"2023-08-04","current":4.300459,"twenty":-7.975949,"median":2.689283,"eighty":4.404916,"marketCap":1988652498},{"date":"2023-08-11","current":4.570433,"twenty":-7.975949,"median":2.689283,"eighty":4.59563,"marketCap":2113495971},{"date":"2023-08-18","current":4.468067,"twenty":-7.975949,"median":2.697608,"eighty":4.598779,"marketCap":2066159488},{"date":"2023-08-25","current":4.417447,"twenty":-7.975949,"median":2.70915,"eighty":4.598779,"marketCap":2042751336},{"date":"2023-09-01","current":4.450069,"twenty":-7.975949,"median":2.713487,"eighty":4.598779,"marketCap":2057836589},{"date":"2023-09-08","current":4.685171,"twenty":-7.975949,"median":2.718459,"eighty":4.660842,"marketCap":2166554448},{"date":"2023-09-15","current":5.306111,"twenty":-7.975949,"median":2.726847,"eighty":4.770664,"marketCap":2453694437},{"date":"2023-09-22","current":5.214995,"twenty":-7.975949,"median":2.726847,"eighty":4.828216,"marketCap":2411559765},{"date":"2023-09-29","current":5.743694,"twenty":-7.975949,"median":2.726847,"eighty":4.944336,"marketCap":2656044900},{"date":"2023-10-06","current":5.586209,"twenty":-7.975949,"median":2.726847,"eighty":5.01406,"marketCap":2583219541},{"date":"2023-10-13","current":5.506342,"twenty":-7.975949,"median":2.726847,"eighty":5.085439,"marketCap":2546286680},{"date":"2023-10-20","current":5.371355,"twenty":-7.975949,"median":2.726847,"eighty":5.164092,"marketCap":2483864943},{"date":"2023-10-27","current":5.320735,"twenty":-10.37185,"median":2.7187,"eighty":5.183723,"marketCap":2460456792},{"date":"2023-11-03","current":5.632314,"twenty":-10.37185,"median":2.7187,"eighty":5.218575,"marketCap":2531201427},{"date":"2023-11-10","current":5.363861,"twenty":-10.37185,"median":2.7187,"eighty":5.29291,"marketCap":2410556891},{"date":"2023-11-17","current":5.898627,"twenty":-10.37185,"median":2.7187,"eighty":5.335852,"marketCap":2650884316},{"date":"2023-11-24","current":6.40214,"twenty":-10.37185,"median":2.7187,"eighty":5.365059,"marketCap":2877166631},{"date":"2023-12-01","current":6.478535,"twenty":-10.37185,"median":2.72267,"eighty":5.38029,"marketCap":2911499120},{"date":"2023-12-08","current":6.762123,"twenty":-10.345708,"median":2.726847,"eighty":5.40405,"marketCap":3038945481},{"date":"2023-12-15","current":6.477378,"twenty":-10.345708,"median":2.726847,"eighty":5.427885,"marketCap":2910978931},{"date":"2023-12-22","current":7.108216,"twenty":-10.37185,"median":2.72267,"eighty":5.478809,"marketCap":3194482061},{"date":"2023-12-29","current":7.112846,"twenty":-10.397993,"median":2.720685,"eighty":5.489704,"marketCap":3196562818},{"date":"2024-01-05","current":7.608257,"twenty":-10.424135,"median":2.7187,"eighty":5.542798,"marketCap":3419203808},{"date":"2024-01-12","current":7.309621,"twenty":-10.424135,"median":2.7187,"eighty":5.590923,"marketCap":3284994987},{"date":"2024-01-19","current":7.808504,"twenty":-10.450277,"median":2.718459,"eighty":5.669951,"marketCap":3509196545},{"date":"2024-01-26","current":7.412639,"twenty":-10.424135,"median":2.7187,"eighty":5.709874,"marketCap":3331291828},{"date":"2024-02-02","current":7.465884,"twenty":-10.424135,"median":2.7187,"eighty":5.766422,"marketCap":3355220533},{"date":"2024-02-09","current":6.990151,"twenty":-10.424135,"median":2.7187,"eighty":5.885655,"marketCap":3141422759},{"date":"2024-02-16","current":6.418502,"twenty":-10.424135,"median":2.7187,"eighty":6.101684,"marketCap":3072081326},{"date":"2024-02-23","current":6.286398,"twenty":-10.424135,"median":2.731024,"eighty":6.221043,"marketCap":3008852573},{"date":"2024-03-01","current":6.219801,"twenty":-10.397993,"median":2.739743,"eighty":6.294914,"marketCap":2976976920},{"date":"2024-03-08","current":6.701206,"twenty":-10.397993,"median":2.752304,"eighty":6.394269,"marketCap":3207391753},{"date":"2024-03-15","current":5.794309,"twenty":-10.397993,"median":2.757333,"eighty":6.40214,"marketCap":2773324387},{"date":"2024-03-22","current":6.171272,"twenty":-10.397993,"median":2.771308,"eighty":6.40214,"marketCap":2953749979},{"date":"2024-03-28","current":6.782062,"twenty":-10.397993,"median":2.782329,"eighty":6.419638,"marketCap":3246091735},{"date":"2024-04-05","current":6.157068,"twenty":-10.424135,"median":2.792386,"eighty":6.450017,"marketCap":2946951333},{"date":"2024-04-12","current":6.902254,"twenty":-10.424135,"median":2.806211,"eighty":6.478304,"marketCap":3303618735},{"date":"2024-04-19","current":7.227863,"twenty":-10.424135,"median":2.821174,"eighty":6.550936,"marketCap":3459464608},{"date":"2024-04-26","current":7.599363,"twenty":-10.397993,"median":2.831103,"eighty":6.604876,"marketCap":3637275337},{"date":"2024-05-03","current":7.904106,"twenty":-10.397993,"median":2.843363,"eighty":6.650657,"marketCap":3425173301},{"date":"2024-05-10","current":7.957211,"twenty":-10.397993,"median":2.851831,"eighty":6.739488,"marketCap":3448185612},{"date":"2024-05-17","current":7.69893,"twenty":-10.397993,"median":2.862085,"eighty":6.836555,"marketCap":3336262099},{"date":"2024-05-24","current":7.872726,"twenty":-10.397993,"median":2.873803,"eighty":6.918183,"marketCap":3411575117},{"date":"2024-05-31","current":8.030833,"twenty":-10.397993,"median":2.87874,"eighty":7.041081,"marketCap":3480089043},{"date":"2024-06-07","current":8.312045,"twenty":-10.397993,"median":2.890347,"eighty":7.110994,"marketCap":3601949691},{"date":"2024-06-14","current":7.809967,"twenty":-10.424135,"median":2.899357,"eighty":7.20537,"marketCap":3384378749},{"date":"2024-06-21","current":8.021177,"twenty":-10.450277,"median":2.908126,"eighty":7.318881,"marketCap":3475904987},{"date":"2024-06-28","current":7.420132,"twenty":-10.485568,"median":2.914426,"eighty":7.344392,"marketCap":3215447466},{"date":"2024-07-05","current":8.845502,"twenty":-10.485568,"median":2.921699,"eighty":7.399675,"marketCap":3833118816},{"date":"2024-07-12","current":8.297562,"twenty":-10.485568,"median":2.930616,"eighty":7.467301,"marketCap":3595673606},{"date":"2024-07-15","current":8.5486,"twenty":-10.485568,"median":2.931522,"eighty":7.489052,"marketCap":3704459076},{"date":"2024-08-02","current":8.040485,"twenty":-10.635885,"median":2.949925,"eighty":7.544826,"marketCap":3392746863},{"date":"2024-08-09","current":7.544899,"twenty":-10.635885,"median":2.968066,"eighty":7.555471,"marketCap":3183630662},{"date":"2024-08-16","current":7.220094,"twenty":-10.635885,"median":2.978269,"eighty":7.601142,"marketCap":3046576565},{"date":"2024-08-23","current":7.176704,"twenty":-10.635885,"median":3.000593,"eighty":7.601142,"marketCap":3028267812},{"date":"2024-08-30","current":7.621762,"twenty":-10.635885,"median":3.027721,"eighty":7.610958,"marketCap":3216063311},{"date":"2024-09-06","current":6.658504,"twenty":-10.635885,"median":3.039541,"eighty":7.610958,"marketCap":2809608986},{"date":"2024-09-13","current":6.653545,"twenty":-10.635885,"median":3.054202,"eighty":7.610958,"marketCap":2807516557},{"date":"2024-09-20","current":6.839502,"twenty":-10.635885,"median":3.066906,"eighty":7.610958,"marketCap":2885982643},{"date":"2024-09-27","current":7.775486,"twenty":-10.635885,"median":3.0801,"eighty":7.62201,"marketCap":3280928609},{"date":"2024-10-04","current":7.686227,"twenty":-10.635885,"median":3.097075,"eighty":7.668336,"marketCap":3243264888},{"date":"2024-10-11","current":7.834992,"twenty":-10.635885,"median":3.133196,"eighty":7.694477,"marketCap":3306037756},{"date":"2024-10-18","current":7.872184,"twenty":-10.635885,"median":3.155214,"eighty":7.749005,"marketCap":3321730974},{"date":"2024-10-25","current":7.435805,"twenty":-10.635885,"median":3.209618,"eighty":7.753419,"marketCap":3137597225},{"date":"2024-10-31","current":8.541869,"twenty":-10.635885,"median":3.232728,"eighty":7.761601,"marketCap":3231756528},{"date":"2024-11-08","current":10.339444,"twenty":-10.638499,"median":3.259831,"eighty":7.813587,"marketCap":3911856437},{"date":"2024-11-15","current":9.190464,"twenty":-10.638499,"median":3.349512,"eighty":7.829517,"marketCap":3477147598},{"date":"2024-11-22","current":10.06568,"twenty":-10.638499,"median":3.38558,"eighty":7.872401,"marketCap":3808279602},{"date":"2024-11-29","current":9.722783,"twenty":-10.638499,"median":3.436207,"eighty":7.907003,"marketCap":3678547000},{"date":"2024-12-06","current":9.213969,"twenty":-10.638499,"median":3.493783,"eighty":7.959307,"marketCap":3486040559},{"date":"2024-12-13","current":8.801939,"twenty":-10.638499,"median":3.56111,"eighty":7.998729,"marketCap":3330152190},{"date":"2024-12-20","current":7.723474,"twenty":-10.638499,"median":3.606796,"eighty":8.015391,"marketCap":2922122233},{"date":"2024-12-27","current":7.482893,"twenty":-10.638499,"median":3.652482,"eighty":8.015391,"marketCap":2831100165},{"date":"2025-01-03","current":7.527138,"twenty":-10.638499,"median":3.69336,"eighty":8.015391,"marketCap":2847839856},{"date":"2025-01-10","current":7.249225,"twenty":-10.641114,"median":3.763091,"eighty":8.01571,"marketCap":2742693675},{"date":"2025-01-17","current":7.516077,"twenty":-10.641114,"median":3.807574,"eighty":8.01571,"marketCap":2843654933},{"date":"2025-01-24","current":7.777397,"twenty":-10.641114,"median":3.823204,"eighty":8.01571,"marketCap":2942523731},{"date":"2025-01-31","current":7.391638,"twenty":-10.641114,"median":3.849654,"eighty":8.01571,"marketCap":2796574554},{"date":"2025-02-07","current":7.359837,"twenty":-10.641114,"median":3.926599,"eighty":8.01571,"marketCap":2784542901},{"date":"2025-02-14","current":11.29089,"twenty":-10.641114,"median":4.243374,"eighty":8.019246,"marketCap":2829530819},{"date":"2025-02-21","current":10.086516,"twenty":-10.641114,"median":4.394139,"eighty":8.037134,"marketCap":2527711235},{"date":"2025-02-28","current":10.426158,"twenty":-10.641114,"median":4.429258,"eighty":8.145007,"marketCap":2612826433},{"date":"2025-03-07","current":10.113771,"twenty":-10.643728,"median":4.464693,"eighty":8.287174,"marketCap":2534541467},{"date":"2025-03-14","current":10.126351,"twenty":-10.643728,"median":4.54681,"eighty":8.536641,"marketCap":2537693881},{"date":"2025-03-21","current":9.878343,"twenty":-10.643728,"median":4.631973,"eighty":8.801939,"marketCap":2475542323},{"date":"2025-03-28","current":10.547385,"twenty":-10.643728,"median":4.683872,"eighty":8.853227,"marketCap":2643206442},{"date":"2025-04-04","current":9.2093,"twenty":-10.643728,"median":4.802266,"eighty":9.064643,"marketCap":2307878204},{"date":"2025-04-11","current":9.17784,"twenty":-10.641114,"median":4.863283,"eighty":9.185414,"marketCap":2299994311},{"date":"2025-04-17","current":9.916094,"twenty":-10.641114,"median":4.957963,"eighty":9.291397,"marketCap":2485002994},{"date":"2025-04-25","current":10.524315,"twenty":-10.643728,"median":5.039055,"eighty":9.480855,"marketCap":2637424921},{"date":"2025-05-02","current":22.634497,"twenty":-10.643728,"median":5.095819,"eighty":9.629986,"marketCap":2386717131},{"date":"2025-05-09","current":22.574683,"twenty":-10.643728,"median":5.168875,"eighty":9.671535,"marketCap":2380410017},{"date":"2025-05-16","current":23.36223,"twenty":-10.643728,"median":5.214214,"eighty":9.722783,"marketCap":2463453687},{"date":"2025-05-23","current":22.335428,"twenty":-10.643728,"median":5.278206,"eighty":9.790675,"marketCap":2355181560},{"date":"2025-05-30","current":23.083099,"twenty":-10.643728,"median":5.313986,"eighty":9.852337,"marketCap":2434020488},{"date":"2025-06-06","current":23.222665,"twenty":-10.643728,"median":5.351129,"eighty":9.893342,"marketCap":2448737088},{"date":"2025-06-13","current":23.45195,"twenty":-10.643728,"median":5.376398,"eighty":9.974476,"marketCap":2472914359}],"updateTime":1749957141227}}}